Natera, Inc. $NTRA Shares Purchased by Osaic Holdings Inc.

Osaic Holdings Inc. raised its position in Natera, Inc. (NASDAQ:NTRA) by 49.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 9,319 shares of the medical research company’s stock after purchasing an additional 3,065 shares during the period. Osaic Holdings Inc.’s holdings in Natera were worth $1,562,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Hilltop National Bank acquired a new position in shares of Natera during the 2nd quarter worth approximately $33,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Natera during the 2nd quarter worth approximately $36,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after buying an additional 106 shares during the period. AlphaQuest LLC increased its stake in Natera by 1,857.1% during the first quarter. AlphaQuest LLC now owns 274 shares of the medical research company’s stock worth $39,000 after acquiring an additional 260 shares during the last quarter. Finally, V Square Quantitative Management LLC purchased a new position in shares of Natera during the 2nd quarter worth $53,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent analyst reports. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. BNP Paribas raised shares of Natera to a “hold” rating and set a $172.00 target price on the stock in a research note on Monday, October 27th. Evercore ISI upped their price target on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. JPMorgan Chase & Co. boosted their price objective on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, Morgan Stanley increased their target price on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Fifteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $231.18.

Natera Stock Down 0.6%

NTRA opened at $229.98 on Wednesday. The business’s 50 day moving average is $219.86 and its two-hundred day moving average is $182.50. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $246.90. The firm has a market cap of $31.81 billion, a price-to-earnings ratio of -100.43 and a beta of 1.63.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the prior year, the company earned ($0.26) EPS. The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. Equities analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 4,692 shares of Natera stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92. Following the transaction, the insider directly owned 113,065 shares in the company, valued at approximately $26,090,879.40. This trade represents a 3.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Rowan E. Chapman sold 4,366 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $243.10, for a total value of $1,061,374.60. Following the sale, the director owned 5,777 shares of the company’s stock, valued at $1,404,388.70. This trade represents a 43.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 336,481 shares of company stock worth $72,008,879 in the last ninety days. Company insiders own 5.63% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.